Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.68 |
| ▸ | ASPH | Q12797 | 2/20 | 0.68 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.68 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | KDM4A | O75164 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | AGER | Q15109 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.40 |
| ▸ | KDM5A | P29375 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30803051 | 1.00 | KDM4E (0.68) | KDM4EASPHKDM8NAPRTTDP1 | |
| SCHEMBL17472117 | 0.83 | KDM4E (0.68) | KDM4EASPHKDM8NAPRTTDP1 | |
| SCHEMBL27189436 | 0.81 | KDM4E (0.46) | KDM4EASPHKDM8NAPRTL3MBTL1 | |
| SCHEMBL30274664 | 0.81 | KDM4E (0.46) | KDM4EASPHKDM8NAPRTTDP1 | |
| SCHEMBL8819772 | 0.81 | NAPRT (0.57) | KDM4EASPHKDM8NAPRTTDP1 | |
| SCHEMBL15527832 | 0.81 | KDM4E (0.46) | KDM4EASPHKDM8NAPRTTDP1 | |
| SCHEMBL28361885 | 0.81 | NAPRT (0.57) | KDM4EASPHKDM8NAPRTTDP1 | |
| SCHEMBL16837130 | 0.79 | NAPRT (0.55) | KDM4EASPHKDM8NAPRTTDP1 | |
| SCHEMBL473869 | 0.79 | KDM4E (0.63) | KDM4EASPHKDM8NAPRTTDP1 | |
| SCHEMBL2027279 | 0.79 | NAPRT (0.55) | KDM4EASPHKDM8NAPRTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118930884-A | Fluorine-containing metal organic framework material for methane and nitrogen separation, and preparation method and application thereof | 浙江工业大学 | 2024-11-12 | — | — | CN | claimed |
| EP-0268775-B1 | METHOD FOR PROTECTING PLANTS AGAINST DISEASES | CIBA-GEIGY AG (CH) | 1992-12-23 | — | — | EP | claimed |
| US-20250304554-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-10-02 | — | — | US | disclosed |
| CN-118930884-A | Fluorine-containing metal organic framework material for methane and nitrogen separation, and preparation method and application thereof | 浙江工业大学 | 2024-11-12 | — | — | CN | disclosed |
| EP-3475275-B1 | 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117658992-A | Benzimidazole compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2024-03-08 | — | — | CN | disclosed |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| CN-109069514-B | Antibacterial compound and application thereof | 结核病药物开发全球联盟公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
| WO-2015160636-A1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015160634-A1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015118057-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2015-08-13 | — | — | WO | disclosed |
| US-20100113421-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
| US-7618960-B2 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| EP-2076492-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-1953154-A1 | MORPHOLINE TYPE CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| WO-2008054605-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113421-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | RTF1, RNGTT, POLR2E | KDM4E 1442/4885ASPH 3359/4885KDM8 512/4885 |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | KDM4E 2674/4885ASPH 2010/4885KDM8 680/4885 |
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | KDM4E 2077/4885ASPH 3213/4885KDM8 2981/4885 |
| US-20250304554-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | KDM4E 2095/4885ASPH 4310/4885KDM8 849/4885 |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | KDM4E 2095/4885ASPH 4310/4885KDM8 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.